查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1781996

神经退化性疾病治疗市场，按药物类型、按疾病适应症、按给药途径、按配销通路、按国家和地区 - 2025 年至 2032 年全球行业分析、市场规模、市场份额和预测

Neurodegenerative Disorder Therapeutics Market, By Drug Type, By Disease Indication, By Route of Administration, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 311 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告重点

2024 年神经退化性疾病治疗市场规模价值 172.439 亿美元，2025 年至 2032 年的复合年增长率为 5.80%。

神经退化性疾病治疗市场-市场动态

人口老化和标靶治疗的进步推动市场成长

全球人口老化和标靶治疗的突破正在重塑神经退化性疾病治疗市场。根据世界卫生组织的数据，全球有超过 5,500 万人患有痴呆症，预计到 2030 年这一数字将上升到 7,800 万，到 2050 年将上升到 1.39 亿。这种人口结构的变化凸显了有效治疗的迫切性。美国国立卫生研究院的 BRAIN 计画等创新研究计画已经开发出先进的基因递送工具，可以精确靶向和激活特定大脑和脊髓细胞中的基因，为阿兹海默症和帕金森氏症等疾病带来希望。同样，欧洲神经退化性疾病研究联合计划 (JPND) 支持跨国项目，以加速治疗进展。这些合作旨在透过创新治疗方法和改善患者护理来减轻神经退化性疾病日益加重的负担。

神经退化性疾病治疗市场—关键见解

根据我们的研究分析师的分析，预计全球市场在预测期内（2025-2032 年）的年复合成长率约为 5.80%。

根据药物类型细分，预计胆碱酯酶抑制剂将在 2024 年占据最大市场份额

根据疾病适应症细分，阿兹海默症是 2024 年最主要的疾病适应症

根据给药途径细分，口服给药是 2024 年最主要的给药途径

按地区划分，北美是 2024 年的主要收入来源

神经退化性疾病治疗市场-細項分析：

全球神经退化性疾病治疗市场根据药物类型、疾病适应症、给药途径、配销通路和地区进行细分。

根据药物类型，市场分为六类：N-甲基-D-天冬胺酸 (NMDA) 受体拮抗剂、多巴胺激动剂、单胺氧化酶-B (MAO-B) 抑制剂、胆碱酯酶抑制剂、免疫调节剂和选择性血清素再摄取抑制剂。胆碱酯酶抑制剂透过增强认知功能，有助于阿兹海默症的治疗。多巴胺激动剂和 MAO-B 抑制剂是控制帕金森氏症症状的关键。 NMDA 受体拮抗剂有助于缓解记忆力减退，而选择性血清素再摄取抑制剂 (SSRI) 和免疫调节剂则有助于缓解神经退化性疾病中的行为症状和发炎。

根据疾病适应症，市场分为五类：阿兹海默症、帕金森氏症、亨廷顿氏症、肌萎缩性侧索硬化症 (ALS) 和多发性硬化症 (MS)。由于全球高发病率和人口老化，阿兹海默症占据主导地位。帕金森氏症的治疗进展强劲，多巴胺标靶药物疗效显着。 ALS 和亨丁顿舞蹈症的治疗方案有限，仍然具有挑战性。多发性硬化症受益于免疫疗法的进步，可改善长期管理和患者生活品质。

神经退化性疾病治疗市场—地理洞察

受医疗基础设施、研究资金和人口老化等因素的影响，神经退化性疾病治疗市场呈现显着的地区差异。北美仍然处于领先地位，美国透过广泛的临床试验、强大的製药实力以及旨在解读复杂脑部疾病的NIH BRAIN计划等倡议做出了主要贡献。欧洲紧随其后，尤其是德国、法国和英国等国家，这些国家的政府支持计画（如JPND（神经退化性疾病研究联合计画））支持跨国研究合作。以日本和中国为首的亚太地区由于老龄人口增长和医疗支出增加而经历快速增长。尤其是日本，其痴呆症发病率位居世界前列，这促使其大力发展先进的治疗方法。同时，拉丁美洲和中东地区正在透过提高意识、政府支持和国际合作逐步扩大其治疗范围，儘管基础设施和可近性在这些地区仍然是发展挑战。

神经退化性疾病治疗市场-竞争格局：

神经退化性疾病治疗市场的竞争格局由製药巨头和专注于创新疗法的新兴生物科技公司共同塑造。百健（Biogen）、罗氏（Roche）、礼来（Eli Lilly）和诺华（Novartis）等公司在开发针对阿兹海默症、帕金森氏症和肌萎缩性脊髓侧索硬化症（ALS）等疾病的标靶生物製剂、基因疗法和单株抗体方面处于领先地位。例如，儘管监管结果不一，百健在淀粉样蛋白标靶疗法方面的工作已引起全球关注。同时，规模较小的生物科技新创公司正在推动基于RNA的疗法、干细胞疗法和神经保护剂的研发，这些研发通常得到与学术机构和政府机构合作的支持。为了克服神经退化性疾病药物试验的高失败率，各公司之间建立了策略联盟、许可协议和联合研究计画。公私合作伙伴关係（尤其是在美国和欧盟）正在培育创新管道，帮助在这个高风险、高需求的治疗领域将早期发现与后期临床成功联繫起来。

最新动态：

2025年4月，处于临床前阶段的生物技术公司Transneural Therapeutics推出了创新神经塑性剂，旨在革新神经精神疾病的治疗方法。这些新型化合物提供了一种比传统迷幻药更安全、更有效的替代品，标誌着下一代精神健康疗法的突破。

2025年5月，赛诺菲宣布收购Vigil Neuroscience，将用于治疗阿兹海默症的在研口服TREM2激动剂VG-3927纳入其神经病学产品线。此举强化了赛诺菲致力于开发创新神经退化性疾病疗法的承诺。

2025年5月，ABLi Therapeutics公司成立，专注于开发由c-Abl激酶活化引起的神经退化性疾病的治疗方法。其主要候选药物Risvodetinib (ABLi-148009)是一种强效、可穿透脑的选择性c-Abl激酶抑制剂，每日口服一次，旨在阻止或逆转帕金森氏症的进展。

目录

第一章：神经退化性疾病治疗市场概述

  • 研究范围
  • 市场估计年限

第二章：执行摘要

  • 市场片段
    • 神经退化性疾病治疗市场（依药物类型）
    • 神经退化性疾病治疗市场片段（依疾病适应症）
    • 神经退化性疾病治疗市场依给药途径划分
    • 神经退化性疾病治疗市场片段（按配销通路）
    • 神经退化性疾病治疗市场（按国家/地区）
    • 神经退化性疾病治疗市场（按地区）
  • 竞争洞察

第三章：神经退化性疾病治疗的关键市场趋势

  • 神经退化性疾病治疗市场驱动因素
    • 市场驱动因素的影响分析
  • 神经退化性疾病治疗市场限制
    • 市场限制的影响分析
  • 神经退化性疾病治疗市场机会
  • 神经退化性疾病治疗市场未来趋势

第四章：神经退化性疾病治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第五章：神经退化性疾病治疗市场：地缘政治紧张局势升级的影响

  • COVID-19 疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：神经退化性疾病治疗市场格局

  • 2024年神经退化性疾病治疗市占分析
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第七章：神经退化性疾病治疗市场－依药物类型

  • 概述
    • 按药物类型分類的细分市场份额分析
    • N-甲基-D-天门冬胺酸（NMDA）受体拮抗剂
    • 多巴胺激动剂
    • 单胺氧化酶-B（MAO-B）抑制剂
    • 胆碱酯酶抑制剂
    • 免疫调节剂
    • 选择性血清素再摄取抑制剂

第 8 章：神经退化性疾病治疗市场 - 依疾病适应症

  • 概述
    • 按疾病适应症分類的细分份额分析
    • 阿兹海默症
    • 帕金森氏症
    • 亨廷顿舞蹈症
    • 肌萎缩侧索硬化症（ALS）
    • 多发性硬化症（MS）

第九章：神经退化性疾病治疗市场－依给药途径

  • 概述
    • 按给药途径分類的细分市占率分析
    • 口服
    • 注射剂
    • 透皮

第 10 章：神经退化性疾病治疗市场 - 按配销通路

  • 概述
    • 按配销通路分類的细分市场份额分析
    • 医院药房
    • 零售药局
    • 网路药局

第 11 章：神经退化性疾病治疗市场 - 按地域划分

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美神经退化性疾病治疗主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模及预测（依药品类型）
    • 北美市场规模及预测（依疾病类型划分）
    • 北美市场规模及预测（按给药途径）
    • 北美市场规模及预测（按配销通路）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲神经退化性疾病治疗主要製造商
    • 欧洲市场规模及预测（按国家/地区）
    • 欧洲市场规模及预测（依药品类型）
    • 欧洲市场规模及预测（依疾病类型划分）
    • 欧洲市场规模及预测（依管理途径）
    • 欧洲市场规模及预测（按配销通路）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区神经退化性疾病治疗主要製造商
    • 亚太地区市场规模及预测（依国家）
    • 亚太地区市场规模及预测（依药品类型）
    • 亚太地区市场规模及预测（依疾病类型划分）
    • 亚太地区市场规模及预测（依管理途径）
    • 亚太地区市场规模及预测（按配销通路）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲神经退化性疾病治疗主要製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（按药物类型）
    • 拉丁美洲市场规模及预测（依疾病类型划分）
    • 拉丁美洲市场规模及预测（依管理途径）
    • 拉丁美洲市场规模及预测（按配销通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲（MEA）
    • 概述
    • 中东和非洲神经退化性疾病治疗主要製造商
    • MEA 市场规模及预测（依国家/地区）
    • MEA 市场规模及预测（依药物类型）
    • MEA 市场规模及预测（依疾病类型划分）
    • MEA 市场规模及预测（依给药途径）
    • MEA 市场规模及预测（依配销通路）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其余地区

第 12 章：神经退化性疾病治疗产业关键供应商分析

  • 竞争仪錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司简介
    • AbbVie Inc.
    • ACADIA Pharmaceuticals Inc.
    • Alector Inc.
    • Allergan PLC
    • Amylyx Pharmaceuticals Inc.
    • Biogen Inc.
    • Boehringer Ingelheim International GmbH
    • Celgene Corporation
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline PLC
    • H. Lundbeck A/S
    • Merck Serono SA
    • Mitsubishi Tanabe Pharma Corporation
    • Novartis International AG
    • Orion Corporation
    • Pfizer Inc.
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
    • UCB SA
    • Others

第 13 章：360 度分析师视角

第 14 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5442

REPORT HIGHLIGHT

Neurodegenerative Disorder Therapeutics Market size was valued at US$ 17,243.90 Million in 2024, expanding at a CAGR of 5.80% from 2025 to 2032.

The Neurodegenerative Disorder Therapeutics Market encompasses treatments aimed at managing or slowing the progression of chronic neurological conditions such as Alzheimer's, Parkinson's, Huntington's disease, and amyotrophic lateral sclerosis (ALS). Rising life expectancy and aging populations worldwide are contributing to a growing patient base, with the World Health Organization estimating that over 55 million people currently live with dementia globally. Despite this, therapeutic development faces significant barriers, including high clinical trial failure rates and the complex nature of neurodegeneration. Limited understanding of disease mechanisms and the blood-brain barrier challenge effective drug delivery. However, the market is witnessing increased investment in gene therapy, monoclonal antibodies, and RNA-based treatments, offering hope for more targeted interventions. Initiatives by national health agencies, such as the U.S. NIH's BRAIN Initiative and Europe's Joint Programme on Neurodegenerative Disease Research (JPND), are creating collaborative frameworks that accelerate innovation and therapeutic advancements in this space.

Neurodegenerative Disorder Therapeutics Market- Market Dynamics

Aging Population and Advancements in Targeted Therapies to Propel Market Growth

The convergence of an aging global population and breakthroughs in targeted therapies is reshaping the neurodegenerative disorder therapeutics market. According to the World Health Organization, over 55 million people worldwide are living with dementia, a number projected to rise to 78 million by 2030 and 139 million by 2050. This demographic shift underscores the urgency for effective treatments. Innovative research initiatives, such as the U.S. National Institutes of Health's BRAIN Initiative, have developed advanced gene delivery tools that precisely target and activate genes in specific brain and spinal cord cells, offering hope for conditions like Alzheimer's and Parkinson's. Similarly, Europe's Joint Programme on Neurodegenerative Disease Research (JPND) supports transnational projects to accelerate therapeutic advancements. These collaborative efforts aim to address the growing burden of neurodegenerative diseases through innovative treatments and improved patient care.

Neurodegenerative Disorder Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.80% over the forecast period (2025-2032)

Based on Drug Type segmentation, Cholinesterase inhibitors were predicted to show maximum market share in the year 2024

Based on Disease Indication segmentation, Alzheimer's disease was the leading Disease Indication in 2024

Based on Route of Administration segmentation, Oral Administration was the leading Route of Administration in 2024

On the basis of region, North America was the leading revenue generator in 2024

Neurodegenerative Disorder Therapeutics Market- Segmentation Analysis:

The Global Neurodegenerative Disorder Therapeutics Market is segmented on the basis of Drug Type, Disease Indication, Route of Administration, Distribution Channel, and Region.

The market is divided into six categories based on Drug Type: N-methyl-D-aspartate (NMDA) Receptor Antagonists, Dopamine Agonists, Monoamine Oxidase-B (MAO-B) Inhibitors, Cholinesterase Inhibitors, Immunomodulators, and Selective Serotonin Reuptake Inhibitors. Cholinesterase inhibitors lead to Alzheimer's care by boosting cognitive function. Dopamine agonists and MAO-B inhibitors are key in managing Parkinson's symptoms. NMDA antagonists help moderate memory loss, while SSRIs and immunomodulators support behavioral symptoms and inflammation in neurodegenerative conditions.

The market is divided into five categories based on Disease Indication: Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Amyotrophic Lateral Sclerosis (ALS), and Multiple Sclerosis (MS). Alzheimer's disease dominates due to high global prevalence and aging demographics. Parkinson's sees strong therapeutic development with dopamine-targeting drugs. ALS and Huntington's remain challenging with limited options. Multiple Sclerosis benefits from immunotherapy advancements, improving long-term management and patient quality of life.

Neurodegenerative Disorder Therapeutics Market- Geographical Insights

The Neurodegenerative Disorder Therapeutics Market demonstrates significant regional variation, driven by healthcare infrastructure, research funding, and aging demographics. North America remains at the forefront, with the United States contributing majorly through extensive clinical trials, strong pharmaceutical presence, and initiatives like the NIH BRAIN Initiative aimed at decoding complex brain disorders. Europe follows closely, particularly in countries like Germany, France, and the UK, where government-backed programs such as JPND (Joint Programme on Neurodegenerative Disease Research) support cross-border research collaborations. The Asia-Pacific region, led by Japan and China, is experiencing rapid growth due to rising elderly populations and increased healthcare spending. Japan, in particular, faces one of the world's highest dementia rates, prompting advanced therapeutic development. Meanwhile, Latin America and the Middle East are gradually expanding their therapeutic reach through growing awareness, government support, and international partnerships, though infrastructure and accessibility remain developmental challenges in these regions.

Neurodegenerative Disorder Therapeutics Market- Competitive Landscape:

The competitive landscape of the Neurodegenerative Disorder Therapeutics Market is shaped by both pharmaceutical giants and emerging biotech firms focusing on novel treatment approaches. Companies like Biogen, Roche, Eli Lilly, and Novartis are leading efforts in the development of targeted biologics, gene therapies, and monoclonal antibodies for conditions such as Alzheimer's, Parkinson's, and ALS. Biogen's work on amyloid-targeting therapies, for instance, has sparked global attention despite mixed regulatory outcomes. Simultaneously, smaller biotech startups are advancing RNA-based treatments, stem cell therapies, and neuroprotective agents, often supported by collaborations with academic institutions and government bodies. Strategic alliances, licensing agreements, and joint research programs are common, as firms aim to overcome the high failure rates of neurodegenerative drug trials. Public-private partnerships, particularly in the U.S. and EU, are fostering innovation pipelines, helping bridge early-stage discoveries and late-stage clinical success in this high-risk, high-need therapeutic domain.

Recent Developments:

In April 2025, Transneural Therapeutics, a preclinical-stage biotech firm, introduced innovative neuroplastogens aimed at transforming treatment for neuropsychiatric disorders. These new compounds offer a safer, more effective alternative to traditional psychedelics, marking a breakthrough in next-generation mental health therapies.

In May 2025, Sanofi announced the acquisition of Vigil Neuroscience, adding VG-3927, an investigational oral TREM2 agonist for Alzheimer's disease, to its neurology pipeline. This move strengthens Sanofi's commitment to developing innovative neurodegenerative disorder therapeutics.

In May 2025, ABLi Therapeutics launched with a focus on developing treatments for neurodegenerative diseases arising from c-Abl kinase activation. Their lead candidate, Risvodetinib (ABLi-148009), is a potent, brain-penetrant, selective c-Abl kinase inhibitor designed for once-daily oral use, aiming to halt or reverse Parkinson's disease progression.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AbbVie Inc.
  • ACADIA Pharmaceuticals Inc.
  • Alector Inc.
  • Allergan PLC
  • Amylyx Pharmaceuticals Inc.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Celgene Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Merck Serono S.A.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Orion Corporation
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.s
  • Others

GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • N-methyl-D-aspartate (NMDA) Receptor Antagonists
  • Dopamine Agonists
  • Monoamine Oxidase-B (MAO-B) Inhibitors
  • Cholinesterase Inhibitors
  • Immunomodulators
  • Selective Serotonin Reuptake Inhibitor

GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY DISEASE INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Alzheimer's Disease
  • Parkinson's Disease
  • Huntington's Disease
  • Amyotrophic Lateral Sclerosis (ALS)
  • Multiple Sclerosis (MS)

GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Injectable
  • Transdermal

GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL NEURODEGENERATIVE DISORDER THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Neurodegenerative Disorder Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Neurodegenerative Disorder Therapeutics Market Snippet by Drug Type
    • 2.1.2. Neurodegenerative Disorder Therapeutics Market Snippet by Disease Indication
    • 2.1.3. Neurodegenerative Disorder Therapeutics Market Snippet by Route of Administration
    • 2.1.4. Neurodegenerative Disorder Therapeutics Market Snippet by Distribution Channel
    • 2.1.5. Neurodegenerative Disorder Therapeutics Market Snippet by Country
    • 2.1.6. Neurodegenerative Disorder Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. Neurodegenerative Disorder Therapeutics Key Market Trends

  • 3.1. Neurodegenerative Disorder Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Neurodegenerative Disorder Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Neurodegenerative Disorder Therapeutics Market Opportunities
  • 3.4. Neurodegenerative Disorder Therapeutics Market Future Trends

4. Neurodegenerative Disorder Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Neurodegenerative Disorder Therapeutics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Neurodegenerative Disorder Therapeutics Market Landscape

  • 6.1. Neurodegenerative Disorder Therapeutics Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Neurodegenerative Disorder Therapeutics Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
    • 7.1.2. N-methyl-D-aspartate (NMDA) Receptor Antagonists
    • 7.1.3. Dopamine Agonists
    • 7.1.4. Monoamine Oxidase-B (MAO-B) Inhibitors
    • 7.1.5. Cholinesterase Inhibitors
    • 7.1.6. Immunomodulators
    • 7.1.7. Selective Serotonin Reuptake Inhibitor

8. Neurodegenerative Disorder Therapeutics Market - By Disease Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Disease Indication, 2024 & 2032 (%)
    • 8.1.2. Alzheimer's Disease
    • 8.1.3. Parkinson's Disease
    • 8.1.4. Huntington's Disease
    • 8.1.5. Amyotrophic Lateral Sclerosis (ALS)
    • 8.1.6. Multiple Sclerosis (MS)

9. Neurodegenerative Disorder Therapeutics Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 9.1.2. Oral
    • 9.1.3. Injectable
    • 9.1.4. Transdermal

10. Neurodegenerative Disorder Therapeutics Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 10.1.2. Hospital Pharmacies
    • 10.1.3. Retail Pharmacies
    • 10.1.4. Online Pharmacies

11. Neurodegenerative Disorder Therapeutics Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Neurodegenerative Disorder Therapeutics Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Neurodegenerative Disorder Therapeutics Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Neurodegenerative Disorder Therapeutics Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Neurodegenerative Disorder Therapeutics Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Neurodegenerative Disorder Therapeutics Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Neurodegenerative Disorder Therapeutics Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. AbbVie Inc.
    • 12.2.2. ACADIA Pharmaceuticals Inc.
    • 12.2.3. Alector Inc.
    • 12.2.4. Allergan PLC
    • 12.2.5. Amylyx Pharmaceuticals Inc.
    • 12.2.6. Biogen Inc.
    • 12.2.7. Boehringer Ingelheim International GmbH
    • 12.2.8. Celgene Corporation
    • 12.2.9. Eli Lilly and Company
    • 12.2.10. F. Hoffmann-La Roche Ltd.
    • 12.2.11. GlaxoSmithKline PLC
    • 12.2.12. H. Lundbeck A/S
    • 12.2.13. Merck Serono S.A.
    • 12.2.14. Mitsubishi Tanabe Pharma Corporation
    • 12.2.15. Novartis International AG
    • 12.2.16. Orion Corporation
    • 12.2.17. Pfizer Inc.
    • 12.2.18. Sanofi S.A.
    • 12.2.19. Teva Pharmaceutical Industries Ltd.
    • 12.2.20. UCB S.A.
    • 12.2.21. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us